Key result
Adriamycin reduces cardiac output and stroke volume without altering myocardial blood flow.
Why the study?
The effects of adriamycin (doxorubicin) on systemic hemodynamics and myocardial blood flow in an intact animal model were not fully characterized.
Does doxorubicin alter systemic hemodynamics and myocardial blood flow in anesthetized rabbits?
Does doxorubicin alter systemic hemodynamics and myocardial blood flow in anesthetized rabbits?
In an intact animal model, doxorubicin decreases cardiac output and stroke volume but does not compromise total coronary blood flow.
Answers are grounded in this paper and cite their sources.
Acute doxorubicin effects in rabbits suggest hemodynamic caution; hypothesis-generating for cardiotoxicity mechanisms, not yet guiding practice.
The effect of adriamycin (doxorubicin) on systemic hemodynamics was assessed in the anesthetized rabbit. Blood flow was measured by the radioactive microsphere method before and 20 min after adriamycin. Cardiac output and stroke volume fell significantly (p less than 0.05), while myocardial blood flow as a proportion of cardiac output and systemic vascular resistance rose significantly (p less than 0.05) after adriamycin. Systemic arterial blood pressure, heart rate, and total myocardial blood flow were not significantly altered. Thus, in the intact animal, adriamycin decreases cardiac output but not at the expense of coronary blood flow.
No takes yet. Share an insight, caveat, or question.
Rabkin et al. (2008) studied this question. Adriamycin (doxorubicin) vs. Baseline (before adriamycin) was evaluated on Systemic hemodynamics including cardiac output and stroke volume (p=<0.05). Adriamycin significantly decreased cardiac output and stroke volume (p<0.05) in anesthetized rabbits, without altering total myocardial blood flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: